keyword
MENU ▼
Read by QxMD icon Read
search

Atomoxetine

keyword
https://www.readbyqxmd.com/read/28432778/cross-species-studies-of-cognition-relevant-to-drug-discovery-a-translational-approach
#1
REVIEW
T W Robbins
This Review advances the case that bidirectional, cross-species translation of findings from experimental animals to and from humans is an important strategy for drug discovery. Animal models of mental disorders require appropriate behavioural or cognitive outcome variables that can be generalized cross-species. One example is the treatment of impulsive behaviour in attention deficit hyperactivity disorder (ADHD) with stimulant drugs. Performance on the stop signal reaction task as an index of impulsivity is improved both in healthy human volunteers and in patients with adult ADHD by stimulant drugs and also by the selective noradrenergic reuptake blocker atomoxetine...
April 22, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28416812/a-new-locus-regulating-micall2-expression-was-identified-for-association-with-executive-inhibition-in-children-with-attention-deficit-hyperactivity-disorder
#2
L Yang, S Chang, Q Lu, Y Zhang, Z Wu, X Sun, Q Cao, Y Qian, T Jia, B Xu, Q Duan, Y Li, K Zhang, G Schumann, D Liu, J Wang, Y Wang, L Lu
Impaired executive inhibition is a core deficit of attention deficit hyperactivity disorder (ADHD), which is a common childhood-onset psychiatric disorder with high heritability. In this study, we performed a two-stage genome-wide association study of executive inhibition in ADHD in Han Chinese. We used the Stroop color-word interference test to evaluate executive inhibition. After quality control, 780 samples with phenotype and covariate data were included in the discovery stage, whereas 922 samples were included in the replication stage...
April 18, 2017: Molecular Psychiatry
https://www.readbyqxmd.com/read/28382197/attention-deficit-hyperactivity-disorder-medication-use-factors-involved-in-prescribing-safety-aspects-and-outcomes
#3
REVIEW
Jose Martinez-Raga, Amparo Ferreros, Carlos Knecht, Raquel de Alvaro, Eloisa Carabal
While treatment of patients with attention-deficit hyperactivity disorder (ADHD) is based on a multimodal approach that combines medication with specific psychological interventions, pharmacotherapy alone is generally considered an essential and cost-effective element. This paper aims to comprehensively and critically review factors involved in prescribing and medication use in individuals diagnosed with ADHD, focusing on the difficulties facing patients with ADHD seeking treatment, as well as the safety and tolerability aspects of ADHD pharmacotherapies, with particular attention on the cardiovascular adverse events and the potential risk of misuse or diversion of ADHD medications...
March 2017: Therapeutic Advances in Drug Safety
https://www.readbyqxmd.com/read/28371725/age-related-pharmacotherapy-of-attention-deficit-hyperactivity-disorder-in-slovenia-in-children-and-adolescents-a-population-based-study
#4
M Stuhec, I Locatelli
BACKGROUND: There are no data on age-related pharmacotherapy for Attention Deficit Hyperactivity Disorder (ADHD) medication in children and adolescents in the most European countries. The main aim of this paper was to obtain that data for children and adolescents in Slovenia. METHOD: The number of ADHD drug prescriptions per patient was obtained from the health claims data on prescription drugs of the Health Insurance Institute of Slovenia for the study period (2003-2015)...
May 2017: European Psychiatry: the Journal of the Association of European Psychiatrists
https://www.readbyqxmd.com/read/28366111/safety-of-treatments-for-adhd-in-adults-pairwise-and-network-meta-analyses
#5
Danielly Chierrito de Oliveira, Patricia Guerrero de Sousa, Camila Borges Dos Reis, Fernanda Stumpf Tonin, Laiza Maria Steimbach, Suzane Virtuoso, Fernando Fernandez-Llimos, Roberto Pontarolo, Andréia Cristina Conegero Sanches
OBJECTIVE: The aim of the study was to analyze evidence comparing the profile of drugs used to treat ADHD in adult patients. METHOD: Systematic searches were conducted in electronic databases. Randomized, double-blind, parallel controlled trials that evaluated the safety of drugs in ADHD were included. The statistical analyses were conducted by pairwise meta-analyses and mixed treatment comparison (MTC). RESULTS: Ten ( n = 3006) trials were included in the analyses...
March 1, 2017: Journal of Attention Disorders
https://www.readbyqxmd.com/read/28356001/atomoxetine-protects-against-nmda-receptor-mediated-hippocampal-neuronal-death-following-transient-global-cerebral-ischemia
#6
Joon Ha Park, Yang Hee Kim, Ji Hyeon Ahn, Soo Young Choi, Seongkweon Hong, Sung Koo Kim, Il Jun Kang, Young-Myeong Kim, Tae-Kyeong Lee, Moo-Ho Won, Choong-Hyun Lee
BACKGROUND: Atomoxetine has been widely used for the treatment of attention-deficit/hyperactivity disorder. ATX has additional abilities such as antagonistic effects on the N-methyl-D-aspartate receptors (NMDARs) and benefit effects in some animal models of neurological disorders. However, there were few studies regarding protective effects and related mechanisms of ATX against cerebral ischemic insults. OBJECTIVE: The objective of this study is to investigate neuroprotection of ATX pretreatment and its mechanisms in the hippocampal cornu ammonis 1 (CA1) region following transient global cerebral ischemia in gerbils...
March 27, 2017: Current Neurovascular Research
https://www.readbyqxmd.com/read/28351466/adhd-in-germany-trends-in-diagnosis-and-pharmacotherapy
#7
Christian J Bachmann, Alexandra Philipsen, Falk Hoffmann
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) sometimes persists into adulthood. There have been no studies from Germany until the present time on the diagnosis and treatment of ADHD over the course of patients' lives, in particular during the transition from adolescence to early adulthood. METHODS: We used nationwide routine data of the AOK statutory healthinsurance fund to determine the frequency of ADHD diagnoses and prescriptions of medication for ADHD...
March 3, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28332006/prenatal-nicotine-exposure-decreases-the-release-of-dopamine-in-the-medial-frontal-cortex-and-induces-atomoxetine-responsive-neurobehavioral-deficits-in-mice
#8
Tursun Alkam, Takayoshi Mamiya, Nami Kimura, Aya Yoshida, Daisuke Kihara, Yuki Tsunoda, Yuki Aoyama, Masayuki Hiramatsu, Hyoung-Chun Kim, Toshitaka Nabeshima
Increased risk of attention-deficit/hyperactivity disorder (AD/HD) is partly associated with the early developmental exposure to nicotine in tobacco smoke. Emerging reports link tobacco smoke exposure or prenatal nicotine exposure (PNE) with AD/HD-like behaviors in rodent models. We have previously reported that PNE induces cognitive behavioral deficits in offspring and decreases the contents of dopamine (DA) and its turnover in the prefrontal cortex (PFC) of offspring It is well known that the dysfunction of DAergic system in the brain is one of the core factors in the pathophysiology of AD/HD...
March 23, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28293899/effects-of-atomoxetine-on-attention-in-wistar-rats-treated-with-the-neurotoxin-n-2-chloroethyl-n-ethyl-2-bromobenzylamine-dsp4
#9
Joachim Hauser, Andreas Reissmann, Thomas-A Sontag, Oliver Tucha, Klaus W Lange
The aim of the present study was to assess the effects of the neurotoxin N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP4), which allows a depletion of noradrenergic terminals in a dose-dependent manner, on attention in rats as measured using the five-choice serial-reaction time task (5CSRTT). In addition, we investigated whether the effects of DSP4 treatment can be reversed by atomoxetine. Atomoxetine is a selective noradrenaline reuptake inhibitor and has been shown to be effective in the treatment of attention deficit hyperactivity disorder...
March 14, 2017: Attention Deficit and Hyperactivity Disorders
https://www.readbyqxmd.com/read/28291572/noradrenaline-transporter-blockade-increases-fronto-parietal-functional-connectivity-relevant-for-working-memory
#10
Dennis Hernaus, Marta Ma Casales Santa, Jan Stefan Offermann, Thérèse Van Amelsvoort
Experimental animal work has demonstrated that dopamine and noradrenaline play an essential role in modulating prefrontal cortex-mediated networks underlying working memory performance. Studies of functional connectivity have been instrumental in extending such notions to humans but, so far, have almost exclusively focussed on pharmacological agents with a predominant dopaminergic mechanism of action. Here, we investigate the effect of a single dose of atomoxetine 60mg, a noradrenaline transporter inhibitor, on working memory performance and associated functional connectivity during an n-back task in 19 healthy male volunteers...
March 10, 2017: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28280346/trend-characteristics-and-pharmacotherapy-of-adults-diagnosed-with-attention-deficit-hyperactivity-disorder-a-nationwide-survey-in-taiwan
#11
Yu-Shian Cheng, Yu-Chiau Shyu, Sheng-Yu Lee, Shin-Sheng Yuan, Chun-Ju Yang, Kang-Chung Yang, Tung-Liang Lee, Liang-Jen Wang
OBJECTIVE: Attention-deficit/hyperactivity disorder (ADHD) in adults may result in functional impairment warranting clinical interventions. However, few studies have investigated the diagnosis and treatment rates of adult ADHD in non-Caucasian ethnic groups. This study used nationwide population-based data to investigate the rate of diagnosis, associated characteristics, and pharmacological treatment for adult ADHD in Taiwan. METHODS: Adults (age ≥18 years) newly diagnosed with ADHD (n=5,397) between January 2000 and December 2011 were enrolled from the National Health Insurance database in Taiwan...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28258319/comparative-efficacy-and-safety-of-attention-deficit-hyperactivity-disorder-pharmacotherapies-including-guanfacine-extended-release-a-mixed-treatment-comparison
#12
REVIEW
Alain Joseph, Rajeev Ayyagari, Meng Xie, Sean Cai, Jipan Xie, Michael Huss, Vanja Sikirica
This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among children and adolescents with ADHD. A Bayesian network meta-analysis was conducted to compare change in symptoms using the ADHD Rating Scale Version IV (ADHD-RS-IV), Clinical Global Impression-Improvement (CGI-I) response, all-cause discontinuation, and adverse event-related discontinuation...
March 3, 2017: European Child & Adolescent Psychiatry
https://www.readbyqxmd.com/read/28256696/-current-state-of-the-attention-deficit-hyperactivity-disorder-approach-in-neuropediatrics
#13
E Cardo, G Ros-Cervera, J Eiris-Punal, C Escofet-Soteras, A Fernandez-Jaen, F Mulas, R Sanchez-Carpintero, A Sans, Grupo de Trabajo de Tdah de la Sociedad Espanola de Neurologia Pediatrica Grupo de Trabajo de Tdah de la Sociedad Espanola de Neurologia Pediatrica
AIM: To know the current state of the approach of attention deficit hyperactivity disorder (ADHD) in neuropediatricians. SUBJECTS AND METHODS: A telematic survey was carried out to collect preliminary information on the interest, difficulties in the management and treatment of ADHD to the 437 fellowship of the Neuropediactric Spanish Society (SENEP). RESULTS: Only 32.49% of the sent questionnaires were answered, with important geographic variability...
February 24, 2017: Revista de Neurologia
https://www.readbyqxmd.com/read/28250566/atomoxetine-induced-hypomania-in-a-patient-with-bipolar-disorder-and-adult-attention-deficit-hyperactivity-disorder
#14
Vijaya Kumar, Shivarama Varambally
Comorbidity of bipolar disorder (BD) with attention deficit hyperactivity disorder (ADHD) is frequent. The management of comorbid ADHD and BD is complicated by the risk of induction of (hypo) mania by the medications used for ADHD treatment. Earlier reports in children and adolescents with ADHD-BD suggest that the possibility of (hypo) mania induction is low when atomoxetine is used along mood stabilizers or antipsychotics. Here, we report induction of hypomania by atomoxetine when used for the treatment of comorbid ADHD in a BD patient while on prophylactic treatment with mood stabilizers...
January 2017: Indian Journal of Psychological Medicine
https://www.readbyqxmd.com/read/28236285/cardiovascular-effects-of-stimulant-and-non-stimulant-medication-for-children-and-adolescents-with-adhd-a-systematic-review-and-meta-analysis-of-trials-of-methylphenidate-amphetamines-and-atomoxetine
#15
REVIEW
Leonie Hennissen, Mireille J Bakker, Tobias Banaschewski, Sara Carucci, David Coghill, Marina Danckaerts, Ralf W Dittmann, Chris Hollis, Hanna Kovshoff, Suzanne McCarthy, Peter Nagy, Edmund Sonuga-Barke, Ian C K Wong, Alessandro Zuddas, Eric Rosenthal, Jan K Buitelaar
BACKGROUND: Many children and adolescents with attention deficit/hyperactivity disorder (ADHD) are treated with stimulant and non-stimulant medication. ADHD medication may be associated with cardiovascular effects. It is important to identify whether mean group effects translate into clinically relevant increases for some individual patients, and/or increase the risk for serious cardiovascular adverse events such as stroke or sudden death. OBJECTIVES: To evaluate potential cardiovascular effects of these treatments, we conducted a systematic review and meta-analysis of the effects of methylphenidate (MPH), amphetamines (AMP), and atomoxetine (ATX) on diastolic and systolic blood pressure (DBP, SBP) and heart rate (HR) in children and adolescents with ADHD...
March 2017: CNS Drugs
https://www.readbyqxmd.com/read/28223809/a-review-of-the-efficacy-of-atomoxetine-in-the-treatment-of-attention-deficit-hyperactivity-disorder-in-children-and-adult-patients-with-common-comorbidities
#16
REVIEW
David B Clemow, Chris Bushe, Michele Mancini, Michael H Ossipov, Himanshu Upadhyaya
Attention-deficit hyperactivity disorder (ADHD) is a common neuropsychiatric disorder that is often diagnosed during childhood, but has also increasingly been recognized to occur in adults. Importantly, up to 52% of children (including adolescents) and 87% of adults with ADHD also have a comorbid psychiatric disorder. The presence of a comorbid disorder has the potential to impact diagnosis and could affect treatment outcomes. Atomoxetine is a nonstimulant treatment for ADHD. Despite numerous published studies regarding efficacy of atomoxetine in the treatment of ADHD in patients with comorbid disorders, there is limited information about the impact of individual common comorbid disorders on the efficacy of atomoxetine for ADHD, especially with regard to adults...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28196459/care-provision-and-prescribing-practices-of-physicians-treating-children-and-adolescents-with-adhd
#17
Ayush Patel, Rohan Medhekar, Melissa Ochoa-Perez, Rajender R Aparasu, Wenyaw Chan, Jeffrey T Sherer, Joy Alonzo, Hua Chen
OBJECTIVE: Care provision and prescribing practices of physicians treating children with attention-deficit hyperactivity disorder (ADHD) were compared. METHODS: A retrospective cohort study was conducted with the 1995-2010 General Electric Centricity Electronic Medical Record database. The sample included children (≤18 years) with newly diagnosed ADHD (ICD-9-CM code 314.XX) who received a prescription for a stimulant or atomoxetine. Identification of comorbid psychiatric disorders, duration from initial ADHD diagnosis to treatment, prescription of other psychotropic medications, and follow-up care during the ten months after the ADHD treatment initiation were compared across provider type (primary care physicians [PCPs], child psychiatrists, and physicians with an unknown specialty)...
February 15, 2017: Psychiatric Services: a Journal of the American Psychiatric Association
https://www.readbyqxmd.com/read/28195837/the-effect-of-atomoxetin-use-in-the-treatment-of-attention-deficit-hyperactivity-disorder-on-the-symptoms-of-restless-legs-syndrome-a-case-report
#18
Saliha Baykal, Melih Nuri Karakurt
Attention-deficit/hyperactivity disorder (ADHD) is frequently accompanied with sleep disorders such as obstructive sleep apnea, periodic limb movement disorder, restless legs syndrome (RLS), and circadian rhythm disorder. We have limited information about the effects of medical therapies used in the treatment of ADHD on RLS. This article discusses the effects of atomoxetine treatment on both disorders in a patient followed by diagnoses of ADHD and RLS.
March 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28167616/towards-trans-diagnostic-mechanisms-in-psychiatry-neurobehavioral-profile-of-rats-with-a-loss-of-function-point-mutation-in-the-dopamine-transporter-gene
#19
Valentina Vengeliene, Anton Bespalov, Martin Roßmanith, Sandra Horschitz, Stefan Berger, Ana L Relo, Hamid R Noori, Peggy Schneider, Thomas Enkel, Dusan Bartsch, Miriam Schneider, Berthold Behl, Anita C Hansson, Patrick Schloss, Rainer Spanagel
The Research Domain Criteria (RDoC) matrix has been developed to reorient psychiatric research towards measurable behavioral dimensions and underlying mechanisms. Here we used a new genetic rat model with a loss of function point mutation in the dopamine transporter (DAT) gene (Slc6a3_N157K) to systematically study the RDoC matrix (www.nimh.nih.gov/research-priorities/rdoc/constructs/rdoc-matrix.shtml). First, we examined the impact of the Slc6a3_N157K mutation on monoaminergic signaling. We then performed behavioral tests representing each of the five RDoC domains - negative and positive valence systems, cognitive, social, and in arousal/regulatory systems...
February 6, 2017: Disease Models & Mechanisms
https://www.readbyqxmd.com/read/28167075/inhibition-of-the-nmda-and-ampa-receptor-channels-by-antidepressants-and-antipsychotics
#20
Oleg I Barygin, Elina I Nagaeva, Denis B Tikhonov, Darya A Belinskaya, Nina P Vanchakova, Natalia N Shestakova
It is known that some antidepressants and antipsychotics directly inhibit NMDA-type ionotropic glutamate receptors. In this study we systematically studied action of seven drugs (Fluoxetine, Citalopram, Desipramine, Amitriptyline, Atomoxetine, Chlorpromazine, and Clozapine) on NMDA receptors and Ca(2+)-permeable and -impermeable AMPA receptors in rat brain neurons by whole-cell patch-clamp technique. Except for weak effect of fluoxetine, all drugs were virtually inactive against Ca(2+)-impermeable AMPA receptors...
April 1, 2017: Brain Research
keyword
keyword
4829
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"